KLP Kapitalforvaltning AS Has $22.45 Million Holdings in Kenvue Inc. $KVUE

Key Points

• KLP Kapitalforvaltning AS increased its stake in Kenvue Inc. by 21.3% in the 2nd quarter, owning $22.45 million worth of shares after purchasing an additional 188,100 shares.
• Kenvue announced a quarterly dividend increase to $0.2075 per share, reflecting a 5.1% dividend yield and a payout ratio of 112.16%.
• Analysts have revised Kenvue's price targets downward, with Bank of America setting a new target of $25.00 while the average target price is currently $22.46.

KLP Kapitalforvaltning AS boosted its stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 21.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,072,646 shares of the company's stock after purchasing an additional 188,100 shares during the quarter. KLP Kapitalforvaltning AS owned 0.06% of Kenvue worth $22,450,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of KVUE. Pittenger & Anderson Inc. acquired a new position in Kenvue during the 1st quarter valued at $30,000. Trust Co. of Vermont raised its stake in Kenvue by 266.8% during the 2nd quarter. Trust Co. of Vermont now owns 1,581 shares of the company's stock valued at $33,000 after purchasing an additional 1,150 shares during the last quarter. TruNorth Capital Management LLC acquired a new position in Kenvue during the 1st quarter valued at $36,000. Truvestments Capital LLC acquired a new position in Kenvue during the 1st quarter valued at $37,000. Finally, Clal Insurance Enterprises Holdings Ltd raised its stake in shares of Kenvue by 378.5% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company's stock valued at $39,000 after buying an additional 1,287 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Trading Up 3.3%

Shares of Kenvue stock opened at $16.21 on Wednesday. The stock has a market capitalization of $31.10 billion, a P/E ratio of 21.90, a price-to-earnings-growth ratio of 2.25 and a beta of 0.72. The company has a quick ratio of 0.68, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. The company has a 50-day simple moving average of $19.46 and a 200 day simple moving average of $21.46. Kenvue Inc. has a 12-month low of $15.47 and a 12-month high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.28 by $0.01. The business had revenue of $3.84 billion during the quarter, compared to analysts' expectations of $3.94 billion. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The firm's revenue for the quarter was down 4.0% on a year-over-year basis. During the same quarter last year, the company posted $0.32 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Research analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th were given a dividend of $0.2075 per share. This is an increase from Kenvue's previous quarterly dividend of $0.21. The ex-dividend date was Wednesday, August 13th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 5.1%. Kenvue's dividend payout ratio is 112.16%.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Bank of America dropped their price objective on shares of Kenvue from $27.00 to $25.00 and set a "buy" rating for the company in a research note on Tuesday, July 15th. Redburn Partners set a $22.00 price objective on shares of Kenvue in a research note on Friday, September 26th. Canaccord Genuity Group dropped their price objective on shares of Kenvue from $29.00 to $26.00 and set a "buy" rating for the company in a research note on Friday, August 8th. JPMorgan Chase & Co. dropped their price objective on shares of Kenvue from $27.00 to $26.00 and set an "overweight" rating for the company in a research note on Friday, July 25th. Finally, Rothschild & Co Redburn upgraded shares of Kenvue from a "neutral" rating to a "buy" rating and dropped their price objective for the company from $22.50 to $22.00 in a research note on Friday, September 26th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $22.46.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.